Stay updated on TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedAdded Revision: v3.4.3; deleted Melanoma and related topics (MedlinePlus Genetics); Revision: v3.4.2.SummaryDifference0.2%

- Check12 days agoChange Detected- Melanoma added as a related topic and a MedlinePlus Genetics entry added to related topics.SummaryDifference0.1%

- Check19 days agoChange DetectedMelanoma and the related topic MedlinePlus Genetics were removed from the page.SummaryDifference0.1%

- Check27 days agoChange DetectedAdded Melanoma as a related topic and linked MedlinePlus Genetics as a related topics resource on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check34 days agoChange DetectedAdded Revision: v3.4.2. Removed the older Revision: v3.4.1 and the government funding operating-status notice.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding lapse notice about the NIH Clinical Center status and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

Stay in the know with updates to TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TILs Plus IL-2 Versus Pembrolizumab in Melanoma Clinical Trial page.